A preclinical evaluation of antimycin a as a potential antilung cancer stem cell agent

Chi-Tai Yeh, Chun Li Su, Chi Ying F Huang, Justin Kung Yi Lin, Wei Hwa Lee, Peter M H Chang, Yu Lun Kuo, Yu Wen Liu, Liang Shun Wang, Chih Hsiung Wu, Yi Shing Shieh, Yi Hua Jan, Yung Jen Chuang, Michael Hsiao, Alexander T H Wu

研究成果: 雜誌貢獻文章同行評審

24 引文 斯高帕斯(Scopus)


Drug resistance and tumor recurrence are major obstacles in treating lung cancer patients. Accumulating evidence considers lung cancer stem cells (CSCs) as the major contributor to these clinical challenges. Agents that can target lung CSCs could potentially provide a more effective treatment than traditional chemotherapy. Here, we utilized the side-population (SP) method to isolate lung CSCs from A549 and PC-9 cell lines. Subsequently, a high throughput platform, connectivity maps (CMAPs), was used to identify potential anti-CSC agents. An antibiotic, antimycin A (AMA), was identified as a top candidate. SP A549 cells exhibited an elevated stemness profile, including Nanog, β-catenin, Sox2, and CD133, and increased self-renewal ability. AMA treatment was found to suppress β-catenin signaling components and tumor sphere formation. Furthermore, AMA treatment decreased the proliferation of gefitinib-resistant PC-9/GR cells and percentage of SP population. AMA demonstrated synergistic suppression of PC-9/GR cell viability when combined with gefitinib. Finally, AMA treatment suppressed tumorigenesis in mice inoculated with A549 SP cells. Collectively, we have identified AMA using CMAP as a novel antilung CSC agent, which acts to downregulate β-catenin signaling. The combination of AMA and targeted therapeutic agents could be considered for overcoming drug resistance and relapse in lung cancer patients.
期刊Evidence-based Complementary and Alternative Medicine
出版狀態已發佈 - 2013

ASJC Scopus subject areas

  • 補充和替代醫學


深入研究「A preclinical evaluation of antimycin a as a potential antilung cancer stem cell agent」主題。共同形成了獨特的指紋。